Targeting the serotonin 2C receptor for the treatment of obesity and type 2 diabetes.
about
A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept.Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trialAVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation.Evidence for a role of 5-HT2C receptors in the motor aspects of performance, but not the efficacy of food reinforcers, in a progressive ratio schedule.
P2860
Targeting the serotonin 2C receptor for the treatment of obesity and type 2 diabetes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting the serotonin 2C receptor for the treatment of obesity and type 2 diabetes.
@en
Targeting the serotonin 2C receptor for the treatment of obesity and type 2 diabetes.
@nl
type
label
Targeting the serotonin 2C receptor for the treatment of obesity and type 2 diabetes.
@en
Targeting the serotonin 2C receptor for the treatment of obesity and type 2 diabetes.
@nl
prefLabel
Targeting the serotonin 2C receptor for the treatment of obesity and type 2 diabetes.
@en
Targeting the serotonin 2C receptor for the treatment of obesity and type 2 diabetes.
@nl
P2860
P921
P356
P1476
Targeting the serotonin 2C receptor for the treatment of obesity and type 2 diabetes.
@en
P2093
Oliver J Marston
P2860
P2888
P304
P356
10.1038/NPP.2008.169
P407
P577
2009-01-01T00:00:00Z